ABSTRACT
In Italy the fertility rate is very low, and an increasing number of patients are infertile and require treatments. The Italian Law concerning the safety of patient care, and the professional liability of health professionals, indicates that health professionals must comply with the recommendations set out in the guidelines developed by public and private bodies and institutions, as well as scientific societies and technical-scientific associations of the health professions, except for specific cases. Unfortunately, no guideline for the diagnosis and the management of infertility is currently available in Italy. In 2019, the Italian Society of Human Reproduction pointed out the need to produce Italian guidelines and subsequently approved the establishment of a multidisciplinary and multiprofessional working group (MMWG) to develop such a guideline. The MMWG was representative of 5 scientific societies, one national federation of professional orders, 3 citizens' and patients' associations, 5 professions (including lawyer, biologist, doctor, midwife, and psychologist), and 3 medical specialties (including medical genetics, obstetrics and gynecology, and urology). The MMWG chose to adapt a high-quality guideline to the Italian context instead of developing one from scratch. Using the Italian version of the Appraisal of Guidelines for Research and Evaluation II scoring system, the National Institute of Clinical Excellence guidelines were selected and adapted to the Italian context. The document was improved upon by incorporating comments and suggestions where needed. This study presents the process of adaptation and discusses the pros and cons of the often-neglected choice of adapting rather than developing new guidelines.
Subject(s)
Gynecology , Infertility , Female , Pregnancy , Humans , Infertility/diagnosis , Infertility/therapy , Birth Rate , Italy , ReproductionABSTRACT
Many studies on gonadotropin treatment in idiopathic OAT have produced inconsistent (75 IU FSH + 75 IU LH) at the dosage of 3 ampoules a week for 90 days in 18 patients with idopathic OAT and testicular volume 12-15 ml. At the end of the cycle seminal fluid parameters and testicular volume were reassessed, comparing them with a homogenous control group including 13 subjects awaiting ICSI, who were not given any kind of pharmacological treatment. Treatment produced a statistically significant improvement in spermatozoa concentration (p = 0.016) and reduction in atypical forms (p = 0.040). We assessed also the impact on oocyte fertilization and pregnancy rates after the use of assisted reproduction techniques in a more restricted group of 8 patients, who had already undergone ICSI cycles before pharmacological therapy. Treatment with menotropin (hMG) appears to improve embryo quality.
